Sera Prognostics Reports on Third Quarter Financial Performance
Sera Prognostics Inc., known as The Pregnancy Company (NASDAQ: SERA), is at the forefront of improving maternal and neonatal health with its innovative pregnancy biomarker insights for medical professionals and patients. The company has revealed its financial outcomes for the third quarter of 2024, which concluded with important developments impacting its operations and future growth.
Key Highlights of Recent Developments
Several recent milestones showcase Sera's commitment to advancing pregnancy care:
Key Study Developments
The current analysis of data from the Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal Outcomes (PRIME) study is significant. Following the locking of the database, efforts are underway to publish these findings, presenting Sera as a leader in the field of maternal health.
Public Awareness Campaigns
Sera has launched an awareness campaign featuring renowned personalities like Dennis Quaid and Meg Ryan. This initiative aims to broadcast information about Sera’s testing and treatment services throughout numerous public television stations and reach over 84 million homes through major networks such as MSNBC and CNN, thereby maximizing public outreach and education.
Consumer Testing Access
Starting from October 2024, Sera has enhanced access to its PreTRM® testing via its website, enabling home sample collection for expectant mothers. This initiative empowers women to receive their test results conveniently, with discussions scheduled with their healthcare providers, which is expected to fuel sales driven by consumer engagement.
Educational Initiatives
Through predictive analytics currently in beta testing, Sera is engaging pregnant women by providing educational material based on extensive data gathered from various pregnancies. This initiative seeks not only to educate but also to forge stronger relationships with expectant mothers.
Team Expansion
Sera is amplifying its commercial capabilities by bolstering its sales and marketing teams with essential new hires aimed at enhancing test adoption results.
Financial Overview for the Third Quarter 2024
For the third quarter of 2024, Sera Prognostics reported a revenue of $29,000, a decrease from $42,000 noted in the same period the previous year. Operating expenses totaled $8.9 million, rising 8% from $8.2 million in Q3 of 2023 as the company navigated necessary product development costs.
Research and development expenditures remained flat at approximately $3.5 million compared to Q3 2023, while selling, general, and administrative expenses increased to $5.4 million from $4.6 million, reflective of strategic investments towards growth.
During this quarter, the company incurred a net loss of $7.9 million, compared to a loss of $7.2 million in the same quarter last year.
Upcoming Conference Call
Sera Prognostics invites interested individuals to join a conference call at 5:00 p.m. Eastern Time today, where they will discuss the operational highlights of the third quarter, alongside financial results and strategic insights. Individuals may dial in via the provided numbers.
About Sera Prognostics, Inc.
Sera Prognostics is a prominent health diagnostics company driven by a mission to enhance the lives of women and babies through precision medicine focused on pregnancy care. With a strong pipeline of innovative diagnostics aimed at predicting preterm birth risk and its associated complications, Sera presents essential insights conducive to proactive and personalized clinical interventions for expectant mothers.
About Preterm Birth
Preterm birth, defined as delivery occurring before 37 weeks of gestation, is notably recognized as a leading factor contributing to infant health complications and long-term health issues. Studies report alarming rates, with significant healthcare costs associated with managing complications arising from prematurity reaching approximately $25 billion annually in recent years.
Frequently Asked Questions
What are the recent highlights from Sera Prognostics?
Sera has initiated an awareness campaign, launched consumer-initiated testing, and enhanced their commercial team while making significant strides in the PRIME study.
How did Sera's financial performance change in Q3 2024?
The revenue dropped from $42,000 in Q3 2023 to $29,000 in Q3 2024, with increased operating expenses also contributing to a net loss of $7.9 million this quarter.
What is PreTRM® testing?
The PreTRM® Test is designed to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies, providing critical data for clinical decision-making.
What initiatives is Sera adopting to improve maternal health?
Sera is focusing on educational outreach, consumer testing capabilities, and strategic partnerships aimed at boosting awareness and improving outcomes associated with pregnancy.
Where can I listen to Sera's conference call?
The conference call can be accessed through dial-in numbers, with additional material available on Sera’s investor relations page.
